Direct Answer
Natera develops and commercializes genetic laboratory tests based on cell-free DNA (cfDNA) analysis. Its three main products are Panorama (non-invasive prenatal testing for chromosomal abnormalities), Signatera (personalized tumor mutation monitoring for cancer treatment response and recurrence detection), and Prospera (organ transplant rejection monitoring). Revenue depends on test volume, reimbursement coverage decisions and the growing adoption of cfDNA-based liquid biopsy across oncology.
What Natera Does
Natera analyzes cell-free DNA circulating in a patient's blood to detect chromosomal abnormalities, tumor-derived DNA and donor-derived DNA from transplanted organs, without requiring invasive tissue samples. The core technology is next-generation sequencing (NGS) of cfDNA coupled with proprietary bioinformatics algorithms that interpret the signal.
Panorama screens for chromosomal conditions (trisomy 21, 18, 13 and sex chromosome aneuploidies) in a maternal blood sample as early as the ninth week of pregnancy, replacing or supplementing earlier invasive testing approaches. Signatera is designed around each patient's tumor mutation profile, creating a personalized assay to track residual tumor DNA in blood after treatment and detect recurrence earlier than imaging alone. Prospera detects donor-derived cfDNA in transplant recipients, providing an early signal of organ rejection before clinical symptoms emerge.
Business Model and Revenue Sources
Natera bills payors (insurance companies and government programs) or patients directly for each test performed. Revenue per test depends on reimbursement coverage: when insurers cover a test category (as Medicare does for Panorama under specific guidelines and as many commercial plans do for Signatera in certain oncology indications), revenue per test is predictable. When coverage is absent, revenue depends on direct patient self-pay or varies by individual insurer determination.
Reimbursement expansion is therefore the primary revenue catalyst: each new Medicare local coverage determination (LCD) for Signatera or expansion of commercial coverage broadens the billable patient population. The company has pursued an aggressive coverage expansion strategy, providing test access while coverage decisions mature, which has driven rapid test volume but also elevated accounts receivable and revenue recognition complexity.
Key Metrics to Track
| Metric | Why It Matters |
|---|---|
| Test volume by product | Primary demand indicator across Panorama, Signatera, Prospera |
| Revenue per test | Reflects reimbursement coverage breadth and mix |
| Gross margin | Lab processing costs vs. revenue; scale leverage |
| Cash runway | Pre-profitability company; burn rate and capital needs |
| Reimbursement coverage decisions | CMS LCDs and commercial plan policies drive revenue ceiling |
Principal Risks
- Reimbursement uncertainty: Coverage decisions by CMS and commercial insurers are uncertain and can be reversed. Adverse coverage decisions significantly reduce addressable revenue.
- Competition from Exact Sciences, Foundation Medicine, Guardant Health: Multiple companies offer cfDNA-based liquid biopsy products; Signatera competes directly with Exact Sciences (Oncotype DX), Guardant (Guardant360) and others in oncology monitoring.
- Capital needs: Natera has been consistently operating at a loss and requires capital to fund test volume growth and coverage infrastructure. Dilution risk is present until profitability is achieved.
- Clinical validation requirements: Expanding Signatera into new cancer types and treatment settings requires prospective clinical trial data, which takes years and capital to generate.
What to Monitor
- Signatera volume growth and any new coverage determinations (CMS or commercial)
- Panorama volume in context of prenatal screening market share
- Prospera adoption in transplant nephrology and other transplant types
- Gross margin improvement as lab scale increases
- Path to operating profitability: cash burn trajectory
FAQ
What is Signatera and why is it important for cancer patients?
Signatera is a personalized, tumor-informed liquid biopsy that detects minimal residual disease (MRD) and recurrence of solid tumors. It is built from each patient's tumor genome, identifying the specific mutations present in their cancer, and then monitors blood for those specific mutation signatures over time. Early detection of circulating tumor DNA can prompt treatment changes before imaging detects a recurrence, potentially improving outcomes in colorectal cancer, breast cancer, bladder cancer and other solid tumor types.
How does Panorama compare to other prenatal tests?
Panorama is a non-invasive prenatal test (NIPT) that analyzes cell-free fetal DNA in maternal blood to screen for chromosomal abnormalities as early as nine weeks of pregnancy. It competes with NIPT tests from Illumina (Verifi), LabCorp (MaterniT), and Quest Diagnostics. Panorama claims differentiation in accuracy for certain aneuploidies and twin pregnancies, and in its ability to report zygosity and fetal sex with high accuracy. Reimbursement coverage for NIPT varies by insurer and gestational risk classification.
What is the status of Natera's path to profitability?
As of mid-2026, Natera generates operating losses on a GAAP basis and has required equity capital raises to fund growth. The company has guided toward gross margin improvement as test volume scales and lab costs are absorbed over a larger revenue base. Operating leverage requires controlling R&D and SG&A growth relative to revenue growth. Investors should monitor the trajectory of gross margin and operating expenses per test rather than absolute loss figures, as the trend toward profitability is the key investment thesis support.
What are local coverage determinations (LCDs) and why do they matter for Natera?
Medicare's coverage for specific diagnostic tests is governed by local coverage determinations issued by Medicare Administrative Contractors (MACs), the regional administrators of Medicare benefits. An LCD for a Natera test (such as Signatera in a specific cancer type and clinical indication) unlocks Medicare reimbursement for that combination of patient and indication, significantly expanding the billable population. LCD expansions are therefore material positive events for Natera's revenue; coverage reversals are material negative events.
How does Prospera work in organ transplant monitoring?
After a kidney (or other organ) transplant, the recipient's immune system may attack the donor organ. Prospera measures the fraction of cell-free DNA in the patient's blood that comes from the donor organ. Elevated donor-derived cfDNA (dd-cfDNA) signals that donor cells are being destroyed, indicating active rejection before clinical symptoms or changes in serum creatinine typically used to detect rejection. Earlier detection allows earlier intervention with immunosuppressants to prevent irreversible organ damage.
References
- Natera Inc. SEC filings (10-K, 10-Q) via SEC EDGAR
- CMS: Local coverage determination database (cms.gov/medicare-coverage-database)